home / stock / alim / alim news

ALIM News and Press, Alimera Sciences Inc. From 05/14/24

Stock Information
Company Name: Alimera Sciences Inc.
Stock Symbol: ALIM
Market: NASDAQ
Website: alimerasciences.com
Menu
ALIM ALIM Quote ALIM Short ALIM News ALIM Articles ALIM Message Board
Get ALIM Alerts

News, Short Squeeze, Breakout and More Instantly...
ALIM - Alimera Sciences GAAP EPS of -$0.12 misses by $0.06, revenue of $23.01M beats by $0.76M

2024-05-14 07:34:18 ET More on Alimera Sciences Seeking Alpha’s Quant Rating on Alimera Sciences Historical earnings data for Alimera Sciences Financial information for Alimera Sciences Read the full article on Seeking Alpha For further details...
ALIM - Alimera Sciences Reports First Quarter 2024 Results

Net Revenue up 70% to $23 Million vs. Q1 2023 Global End User Demand Up 23% vs. Q1 2023 Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global p...

ALIM - Alimera Sciences Q1 2024 Earnings Preview

2024-05-13 13:39:39 ET More on Alimera Sciences Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Alimera Sciences Historical earnings data for Alimera Sciences Financial information for Alimera Sciences ...

ALIM - Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences

ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today it ...
ALIM - Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update

ATLANTA, April 30, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will repo...

ALIM - The top stocks with buying pressure across the Russell universe - Jefferies

2024-03-20 11:40:23 ET More on iShares Russell 1000 Growth ETF, iShares Russell 2000 ETF, etc. IWF ETF: Solid Track Record, But Looks Overextended Now IWM: Are Small Caps Being Overlooked In The Megacap Market Frenzy? IWM: Super Micro Computer Is Leading The Russell ...

ALIM - Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better...
ALIM - Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that th...

ALIM - ALIM Stock Earnings: Alimera Sciences Beats Revenue for Q4 2023

2024-03-07 12:52:07 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alimera Sciences (NASDAQ: ALIM ) just reported results for the fourth quarter of 2023. Alimera Sciences reported earnings per share of -7 cents. The company reported r...

ALIM - Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript

2024-03-07 12:39:07 ET Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Conference Call March 07, 2024 09:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President & Chief Executive Officer Elliot Maltz - Chief Financial Off...
Previous 10 Next 10